Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Phase 1 Completed 32 enrolled AstraZeneca

Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.

Timeline

Start: 2011-06
Primary completion: 2011-10
Completion: 2011-11

Publications

Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014 Dec;54(12):1375-82. doi: 10.1002/jcph.349. Epub 2014 Jul 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naloxegol	Small molecule	25 mg	—

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Summary

Timeline

Publications

Drugs

Indications